TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00981955

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine and L-theanine
Description: Acute oral administration of 75mg of caffeine, 50mg l-theanine, 75mg caffeine and 50mg l-theanine in combination or placebo. One dosage administered on each of four separate study days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine and L-theanine
Description: Acute oral administration of 75mg of caffeine, 50mg l-theanine, 75mg caffeine and 50mg l-theanine in combination or placebo. One dosage administered on each of four separate study days.
Study: NCT02630459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: erenumab via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: erenumab via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: erenumab via autoinjector (AI)/pen
Study: NCT00981955

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine and L-theanine
Description: Acute oral administration of 75mg of caffeine, 50mg l-theanine, 75mg caffeine and 50mg l-theanine in combination or placebo. One dosage administered on each of four separate study days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine and L-theanine
Description: Acute oral administration of 75mg of caffeine, 50mg l-theanine, 75mg caffeine and 50mg l-theanine in combination or placebo. One dosage administered on each of four separate study days.
Study: NCT04483908

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: 2x 10ml of blood, one vial to obtain the antibodies and one vial in ethylenediaminetetraacetic acid (EDTA) (or citrate-treated) to obtain peripheral blood mononuclear cells (PBMCs)

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: 2x 10ml of blood, one vial to obtain the antibodies and one vial in ethylenediaminetetraacetic acid (EDTA) (or citrate-treated) to obtain peripheral blood mononuclear cells (PBMCs)

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: 2x 10ml of blood, one vial to obtain the antibodies and one vial in ethylenediaminetetraacetic acid (EDTA) (or citrate-treated) to obtain peripheral blood mononuclear cells (PBMCs)

Intervention type: DIAGNOSTIC_TEST
Intervention: blood draw
Description: 2x 10ml of blood, one vial to obtain the antibodies and one vial in ethylenediaminetetraacetic acid (EDTA) (or citrate-treated) to obtain peripheral blood mononuclear cells (PBMCs)

Intervention type: DIAGNOSTIC_TEST
Intervention: fingertip tests for POC assays
Description: performing POC test by taking two blood drops from the fingertip

Intervention type: DIAGNOSTIC_TEST
Intervention: fingertip tests for POC assays
Description: performing POC test by taking two blood drops from the fingertip

Intervention type: DIAGNOSTIC_TEST
Intervention: fingertip tests for POC assays
Description: performing POC test by taking two blood drops from the fingertip

Intervention type: DIAGNOSTIC_TEST
Intervention: saliva collection
Description: saliva collection: the patient delivers saliva into an adsorbent filter, which is placed in the Salivette tube, centrifuged at 1,600x g for 15 min at 4°C to remove cells and debris. Native supernatant is used for testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: saliva collection
Description: saliva collection: the patient delivers saliva into an adsorbent filter, which is placed in the Salivette tube, centrifuged at 1,600x g for 15 min at 4°C to remove cells and debris. Native supernatant is used for testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: saliva collection
Description: saliva collection: the patient delivers saliva into an adsorbent filter, which is placed in the Salivette tube, centrifuged at 1,600x g for 15 min at 4°C to remove cells and debris. Native supernatant is used for testing.

Intervention type: DIAGNOSTIC_TEST
Intervention: collection of swabs
Description: collection of nasopharyngeal and oropharyngeal swabs for PCR testing on the control group (eg negative subpopulation)
Study: NCT04528979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioRoot RCS® root canal sealer
Description: Root canal obturation with guttapercha and BioRoot RCS® root canal sealer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioRoot RCS® root canal sealer
Description: Root canal obturation with guttapercha and BioRoot RCS® root canal sealer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AH Plus® root canal sealer
Description: Root canal obturation with guttapercha and AH Plus® root canal sealer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AH Plus® root canal sealer
Description: Root canal obturation with guttapercha and AH Plus® root canal sealer
Study: NCT00226954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Study: NCT00326950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle. The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2.
Study: NCT00519818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort
Description: Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortef
Description: Cortef 3 times daily(total dose 30 mg)for minimum of 7 days
Study: NCT01882374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: Injection, 300mcg/kg/day for 28 days
Study: NCT02630459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: erenumab via autoinjector (AI)/pen
Study: NCT04008992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BMS-986259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BMS-986259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BMS-986259

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P-Aminohippurate
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P-Aminohippurate
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P-Aminohippurate
Description: Diagnostic Agent
Study: NCT01453439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based CBT. During the sessions, participants will receive education about BDD and CBT, learn to develop more helpful thoughts and beliefs, gradually enter anxiety provoking situations while reducing compulsions (repetitive behaviors), and learn relapse prevention techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based SPT. During the sessions, participants will receive education about BDD and SPT, learn about factors that may affect their symptoms (for example, relationships, work, stress), and learn to cope with challenges in their life by improving self-esteem and positive coping skills.
Study: NCT04008992

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P-Aminohippurate
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P-Aminohippurate
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P-Aminohippurate
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P-Aminohippurate
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P-Aminohippurate
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P-Aminohippurate
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P-Aminohippurate
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P-Aminohippurate
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P-Aminohippurate
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P-Aminohippurate
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Diagnostic Agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Diagnostic Agent
Study: NCT04095130

Intervention type: DIAGNOSTIC_TEST
Intervention: 23Na Magnetic resonance imaging
Description: Measurement of skin sodium content by non-invasive 23Na Magnetic resonance imaging.

Intervention type: DIAGNOSTIC_TEST
Intervention: 23Na Magnetic resonance imaging
Description: Measurement of skin sodium content by non-invasive 23Na Magnetic resonance imaging.
Study: NCT02571660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GINA treatment fot asthma +vit.D low supplementation dose
Description: Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GINA treatment fot asthma +vit.D high supplementation dose
Description: Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
Study: NCT02535299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin(1500mg-2000mg/day) treatment for 6 months
Study: NCT03502304

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training plus resistant training
Description: CT in women with prediabetes and co-morbidities associated. Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 2 groups proposed. All sessions will be supervised by an exercise physiologist during 20-weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training plus resistant training
Description: CT in women with prediabetes and co-morbidities associated. Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 2 groups proposed. All sessions will be supervised by an exercise physiologist during 20-weeks.
Study: NCT03468972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment
Description: At 3 months after randomization, patients in the corticosteroid arm who have persistent proteinuria of ≥ 1.0 g/g creatinine, or fast decline in eGFR ≥ 15% from the baseline value, will additionally receive cyclosphosphamide during the following 3 months. Patients who have substantial decreased amount of proteinuria \< 1.0 g/g creatinine at 3 months will continue protocol-based corticosteroids during the same period. At 6 months after randomization, patients who receive add-on cyclophosphamide will switch to azathioprine as a maintenance therapy and those who receive corticosteroids alone will discontinue the treatment and will be followed up during 24 months thereafter. Assessment of outcome will be done at 6 months and at 36 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intensive supportive care
Description: During 3-6 months before the enrollment, all patients will receive maximal supportive care including the use of RAS blockers, blood pressure control with a target of \<130/80 mmHg, and protein restriction diet. If proteinuria does not decrease \< 1.0 g/g creatinine, patients will be randomly assigned to continue supportive care, or to receive corticosteroids.
Study: NCT02008422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gimeracil and Oteracil Potassium Capsule
Description: 40 mg/m2, po., Bid., d1-14, 21 d as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimeracil and Oteracil Potassium Capsule
Description: 40 mg/m2, po., Bid., d1-14, 21 d as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar injection
Description: 7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10, 21 d as a cycle.
Study: NCT03824405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BTX 1204
Description: BTX 1204 liquid formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle liquid formulation
Study: NCT00650455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 10 mg tablet once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: naproxen 500 mg capsule twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet every morning and capsule every evening for 12 weeks
Study: NCT02166645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone position
Description: Participants of intervention group will be placed in prone position immediately after extubation and positioned over a roll to raise the chest and facilitate diaphragmatic dynamic, with lateralized head and aligned with the trunk, upper and lower limbs flexed and hands near the face, facilitating hand-mouth access.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supine position
Description: Participants of control group remain in supine position after extubation and positioned with the head in the midline, with the upper side of the thorax and brought forward and rolls down the legs to promote slight flexion (30-40º) in the hips and knees.
Study: NCT02654236

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Obeticholic Acid (OCA)
Description: 10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
Study: NCT00377559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non pegylated liposomal doxorubicin and docetaxel
Description: max. 6 courses
Study: NCT01762267

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition intervention
Description: DASH diet control diet
Study: NCT02588170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Study: NCT00874523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atazanavir plus raltegravir
Description: atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atazanavir plus raltegravir
Description: atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks
Study: NCT02316067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The CHORDATA® Method (16 sessions; 50 minutes each; twice a week) consisted of three exercises: (1) anterior pendulum, with the patient seated on a chair, upper limb suspended by springs and straps, and actively moving the trunk forward; (2) posterior pendulum exercise, on a similar position as exercise (1) but now moving the trunk backwards and recruiting the abdominal wall muscles during a posterior pelvic tilt motion; and (3) stand-up and sit-down exercise, patient with knees fixed anteriorly, initiating the standing-up movement by pulling back and down the springs, trying to maintain the standing position for as long as possible, balancing the trunk and transferring the supporting force from the upper limbs to the lower limbs.
Study: NCT04500210

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in gelatin capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric
Description: Turmeric in gelatin capsules
Study: NCT02542878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foam roller
Description: A bout of 60 seconds of myofascial release with foam roller
Study: NCT03756688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX PTT - 6 months
Description: Penile traction therapy in straight position for all 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX PTT - 6 months
Description: Penile traction therapy in straight position for all 6 months.
Study: NCT06300866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test
Description: test toothpaste containing 0.45% stannous fluoride
Study: NCT03756688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX PTT - 3 months
Description: Penile traction therapy in straight position for first phase (3 months)
Study: NCT02093481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Priming
Description: The reference or test meal was eaten 3 days prior to measurements of variables.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Priming
Description: The reference or test meal was eaten 3 days prior to measurements of variables.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No priming
Description: The reference or test meal was eaten 1 days prior to measurements of variables.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No priming
Description: The reference or test meal was eaten 1 days prior to measurements of variables.
Study: NCT00750711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation for atrial flutter by catheters
Study: NCT03813004

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reaction for gait perturbation
Description: Participants were subjected to four different perturbation types while walking on the treadmill:~1. left treadmill belt deceleration for right leg toe off~2. right treadmill belt deceleration for left leg toe off~3. left treadmill belt acceleration for right leg heel strike~4. right treadmill belt acceleration for left leg heel strike~Motion analysis was conducted to analyze effect of the intervention on gait.
Study: NCT02091284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation
Description: Direct currents were transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode was placed over F3 according to the 10-20 international system while the anode was placed over the contralateral F4 region. The currents flowed continuously for 20 minutes with an intensity of 2 milliamperes.
Study: NCT01517269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent education with human patient simulator
Description: After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management using teaching vignettes and practice with human patient simulator
Study: NCT06300866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test
Description: test toothpaste containing 0.45% stannous fluoride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: toothpaste containing 0.76% sodium monofluorophosphate
Study: NCT01517269

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management without the use of a simulator
Study: NCT01912846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive advance care planning
Description: The facilitator will begin each course of intervention by assessing the patient's and his/her family caregiver's readiness for engagement in ACP independently.~Providing participant-centered care tailored to the specific needs of participants at each stage of readiness for engagement in ACP.~Facilitating EOL care discussions throughout the dying process.~A workbook and a video decision aid that briefly describes ACP to enhance participants' understanding of the essential elements in ACP.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Attention usual care
Description: a consistent master prepared nurse on the study team will provide the attention portion of the care. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department..